ProCE Banner Activity

Selection of Optimal Islatravir Doses for Persons With HIV Naive to Treatment and Switching From Stable Therapy Through Modeling and Simulation

Slideset Download
Conference Coverage

In models and simulations, islatravir 0.25 mg daily was predicted to have lymphocyte and CD4+ T-cell increases similar to standard ART.

Released: November 01, 2022


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare